Navidea Biopharmaceuticals, Inc. Overview
Pro stress-test →Navidea Biopharmaceuticals is a precision medicine company developing immunodiagnostic agents and immunotherapeutics for cancer, autoimmune, infectious, and inflammatory diseases. However, the company filed for Chapter 11 bankruptcy in October 2025 and is currently undergoing asset liquidation proceedings, representing a complete operational and financial collapse.
Strategic Profile
Pro stress-test →The company's core technology platform, Manocept™, targets the CD206 mannose receptor on activated macrophages for diagnostic imaging and therapeutic delivery. Prior to bankruptcy, Navidea had generated meaningful revenues from the 2017 sale of Lymphoseek® rights to Cardinal Health. The bankruptcy auction process completed in January 2026 signals the end of the company as an independent operating entity.
Competitive Landscape
Pro stress-test →Navidea's Manocept platform was designed to compete in the macrophage-targeted diagnostic and therapeutic space, positioned against conventional cancer imaging and autoimmune diagnostic approaches. However, bankruptcy has eliminated the company as a competitive market participant. Potential competitors in immunodiagnostic space include larger biopharmaceutical firms with established oncology and rheumatology portfolios.
Industry Context
Navidea Biopharmaceuticals, Inc. operates in Immunodiagnostic imaging and immunotherapeutics.
Key facts
Founded: 1990s · Headquarters: Dublin, Ohio, US · Employees: N/A (bankruptcy liquidation) · Revenue: N/A (non-operating) · Market cap: $0 (bankruptcy liquidation)